Get started
Author

Martin Frenzel

Observed names: M Frenzel, M. Frenzel, Martin J. Frenzel
Observed institutions: Royal Marsden NHS Foundation Trust, Mayo Clinic, Kaiser Permanente, Eli Lilly (United States), University of California, San Francisco, Universität Ulm, Kyoto University, Sheba Medical Center, Universitair Ziekenhuis Leuven, Baylor University Medical Center, Centre Hospitalier Universitaire de Besançon, Osaka National Hospital, Sarah Cannon, Centre Léon Bérard, Institut de Cancérologie de l'Ouest, Dana-Farber Cancer Institute, National Cancer Center, Saitama Cancer Center, University of Pittsburgh Medical Center, Tennessee Oncology, Hospital Universitario Ramón y Cajal, Vall d'Hebron Institute of Oncology, Yonsei Cancer Hospital, Ludwig-Maximilians-Universität München, Stanford University
OpenAlex ID: A5040919295
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
2017 · Matthew P. Goetz, Masakazu Toi, et al. · Journal of Clinical Oncology · 1,738
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017 · George W. Sledge, Masakazu Toi, et al. · Journal of Clinical Oncology · 1,677
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
2020 · Stephen R. D. Johnston, Nadia Harbeck, et al. · Journal of Clinical Oncology · 1,046
PDF
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
2019 · George W. Sledge, Masakazu Toi, et al. · JAMA Oncology · 988
PDF
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
2016 · Amita Patnaik, Lee S. Rosen, et al. · Cancer Discovery · 741
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
2019 · Stephen Johnston, Miguel Martin, et al. · npj Breast Cancer · 684
PDF
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
2017 · Maura N. Dickler, Sara M. Tolaney, et al. · Clinical Cancer Research · 676
PDF
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
2016 · Shubham Pant, Suzanne F. Jones, et al. · European Journal of Cancer · 92
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
2018 · Angelo Di Leo, Joyce O’Shaughnessy, et al. · npj Breast Cancer · 66
PDF
MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.
2016 · Maura N. Dickler, Sara M. Tolaney, et al. · Journal of Clinical Oncology · 65
Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
2014 · Amita Patnaik, Lee S. Rosen, et al. · Cancer Research · 42
LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.
2014 · Amita Patnaik, Lee S. Rosen, et al. · Journal of Clinical Oncology · 42
Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.
2014 · Jonathan Wade Goldman, Leena Gandhi, et al. · Journal of Clinical Oncology · 27
MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
2019 · G.W. Sledge, M. Toi, et al. · Annals of Oncology · 23
PDF
MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer
2017 · A. Di Leo, M. Toi, et al. · Annals of Oncology · 20
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
2017 · George W. Sledge, Masakazu Toi, et al. · Journal of Clinical Oncology · 18
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer—Reply
2020 · George W. Sledge, Martin Frenzel · JAMA Oncology · 17
MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).
2015 · Matthew P. Goetz, Masakazu Toi, et al. · Journal of Clinical Oncology · 16
Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer
2015 · Sara M Tolaney, Lee S Rosen, et al. · Cancer Research · 13
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
2020 · Hope S. Rugo, Veronique Dieras, et al. · Breast Cancer Research and Treatment · 9
PDF
Abstract OT1-1-07: A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)
2015 · Antonio Llombart, Masakazu Toi, et al. · Cancer Research · 9
The association of early toxicity and outcomes for patients treated with abemaciclib.
2018 · Hope S. Rugo, George W. Sledge, et al. · Journal of Clinical Oncology · 8
Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)
2016 · Sara A. Hurvitz, Jeanne Marie Schilder, et al. · Cancer Research · 4
Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis
2018 · Matthew P. Goetz, Miguel Martin, et al. · Cancer Research · 3
Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer
2018 · P Rastogi, M Toi, et al. · Cancer Research · 3
Works count: 42
Citation count: 8,037
H-index: 17
I10-index: 19
Year
Topic
Type